Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | CD44 | P16070 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9157680 | 0.78 | CYP2A6 (0.45) | CYP3A4NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Biphenyl SCHEMBL27962710 | 0.76 | KMT2A (0.37) | PRCPHTR2CSIGMAR1DRD2ALDH1A1 | |
| SCHEMBL4723655 | 0.71 | NISCH (0.41) | SIGMAR1HTR2AHTR7NPC1RAB9A | |
| SCHEMBL3173611 | 0.70 | HTR7 (0.44) | HTR2CSIGMAR1DRD2HTR2AHTR7 | |
| SCHEMBL3281172 | 0.70 | PRCP (0.51) | PRCPPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL3283120 | 0.69 | PRCP (0.50) | PRCPPNMTCD44MAOBDRD2 | |
| Hydrochloric Acid SCHEMBL3281306 | 0.69 | CD274 (0.43) | SIGMAR1HTR7NPC1 | |
| SCHEMBL1534886 | 0.67 | ALDH1A1 (0.42) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL498076 | 0.67 | ATM (0.39) | NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| Benzene SCHEMBL29043008 | 0.67 | TSHR (0.33) | APEX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | claimed |
| WO-2001096339-A1 | NOVEL TELOMERASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-20 | — | — | WO | claimed |
| WO-2024148184-A1 | COMPOUNDS AND PROCESSES FOR THE PREPARATION OF JAK INHIBITORS | AERIE PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| EP-4363058-A1 | AZETIDINYL PYRIMIDINES AND USES THEREOF | Aerie Pharmaceuticals, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117642395-A | Azetidinyl pyrimidines and their use | 爱瑞制药公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20240002392-A1 | Azetidinyl Pyrimidines and Uses Thereof | ALCON INC. (CH) | 2024-01-04 | — | — | US | disclosed |
| WO-2024006916-A1 | AZETIDINYL PYRIMIDINES AND USES THEREOF AS JAK INHIBITORS | AERIE PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2023279105-A1 | AZETIDINYL PYRIMIDINES AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-1926721-B1 | THIOPHENE AND THIAZOLE SUBSTITUTED TRIFLUOROETHANONE DERIVATIVES AS HISTONE DEACETYLASE (HDAC) INHIBITORS | MSD ITALIA SRL (IT) | 2016-05-04 | — | — | EP | disclosed |
| US-8779202-B2 | Compositions and methods for the treatment of giardiasis | GEORGETOWN UNIVERSITY (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140155493-A1 | BIS-AROMATIC ANTICANCER AGENTS | THE UAB RESEARCH FOUNDATION (US) | 2014-06-05 | — | — | US | disclosed |
| WO-2006103544-A2 | 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006005941-A1 | AMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGELETTI S.P.A. (IT) | 2006-01-19 | — | — | WO | disclosed |
| US-20030186978-A1 | Novel telomerase inhibitors | PHARMACIA ITALIA, SPA (IT) | 2003-10-02 | — | — | US | disclosed |
| WO-2001096339-A1 | NOVEL TELOMERASE INHIBITORS | PHARMACIA ITALIA S.P.A. (IT) | 2001-12-20 | — | — | WO | disclosed |
| US-6051572-A | Azetidine, pyrrolidine and piperidine derivatives | MERCK SHARP & DOHME LTD. (GB) | 2000-04-18 | — | — | US | disclosed |
| WO-1997016445-A1 | AZETIDINE, PYRROLIDINE AND PIPERIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002392-A1 | Azetidinyl Pyrimidines and Uses Thereof | JAK2, JAK1, JAK3 | PRCP 1743/4885HTR2C 2919/4885SIGMAR1 4150/4885 |
| US-20140155493-A1 | BIS-AROMATIC ANTICANCER AGENTS | TP53, APC, OAT | PRCP 2111/4885HTR2C 4224/4885SIGMAR1 2566/4885 |
| US-20030186978-A1 | Novel telomerase inhibitors | TERT, TERF2IP, TERF2 | PRCP 888/4885HTR2C 4823/4885SIGMAR1 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.